Navigation Links
Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
Date:2/9/2011

e escalation safety study in adults with Stage III/IV metastatic melanoma was initiated in December 2010 and is currently underway.

"We are very excited about the anti-GITR program, notably the unique and multifaceted mechanism of action and its promising safety profile," said Tony deFougerolles, Tolerx Chief Scientific Officer. "The preclinical data indicate that TRX518 has tremendous potential for enhancing anti-tumor responses, regardless of tumor type, and for also improving the effectiveness of other cancer therapies including chemotherapeutics and cancer vaccines."

About TRX518

TRX518 is an investigational immunotherapy designed to activate GITR (glucocorticoid-induced tumor necrosis factor receptor) found on multiple types of T cells and other immune cells. GITR plays a role in directing the anti-tumor immune response via a multifaceted mechanism of action that includes activating tumor antigen-specific T effector cells, abrogating the suppression induced by T regulatory cells, and activating NK cells. In preclinical studies, TRX518 achieved its effect without compromising normal immune function, and preclinical models suggest TRX518 to have a favorable safety profile. A Phase 1 clinical study of TRX518, a first-in-class anti-GITR monoclonal antibody, has been initiated to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ascending single doses of TRX518 in patients with malignant melanoma. TRX518 is designed to have activating and sustaining effects on T cells for enhancing the immune system's responses against cancer cells, including responses that may occur with TRX518 alone, as well as complementary responses in combination with other cancer therapies including vaccines. 

About Tolerx

Tolerx, Inc., a world leader in immunology for novel drug development, has a portfolio of innovative, first-in-class drug candidates to treat autoimmune diseases, d
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
2. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
3. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
4. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
7. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
8. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
11. Watson Presents Outlook for Continued Long Term Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) (Intercept), ... and commercialization of novel bile acid therapeutics to treat ... announced that Mark Pruzanski , MD, ... Deutsche Bank Securities 38th Annual Health Care Conference in ... 2013 at 4:10 p.m. ET. About Intercept ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, ... announced today that it will present new results ... an industry conference sponsored by the PML Consortium ... Idec).  JC polyomavirus (JCV) is the causative agent ... tyrosine kinase inhibitor in an extended release formulation, ...
(Date:5/23/2013)... 23, 2013  PAREXEL International Corporation (NASDAQ: ... at the Jefferies Healthcare Conference in New York.  ... Chief Financial Officer, will be making a presentation on ... Monday, June 3, 2013. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2PAREXEL International To Present At Jefferies Healthcare Conference 2
... March 20, 2012  OriGene Technologies today announced the ... and extensively validated monoclonal antibodies under the UltraMAB™ ... antibodies which are exclusively developed by OriGene for ... products available on the market that have been ...
... YORK, March 20, 2012 Reportlinker.com announces that ... its catalogue: The Outlook ... http://www.reportlinker.com/p0192645/The-Outlook-for-Medical-Devices-in-Central-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Facility The ... total market of 303 million people and a ...
Cached Medicine Technology:OriGene Technologies Announces the Release Specificity-Verified UltraMAB™ Antibodies 2The Outlook for Medical Devices in Central Asia 2The Outlook for Medical Devices in Central Asia 3The Outlook for Medical Devices in Central Asia 4
(Date:5/23/2013)... - Even while being dragged to its destruction ... fires away, sending signals that thwart the development ... reported in an early online publication at ... often encountered by tumors, the epidermal growth factor ... an international team led by scientists at The ...
(Date:5/23/2013)... May 23, 2013 The Rottenstein Law ... firm, has created the Tylenol Lawsuit Information Center at ... Tylenol users and those who are considering filing lawsuits. ... to potentially cause severe liver damage, according to a ... In the “safety communication,” the FDA warned consumers ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
(Date:5/23/2013)... 2013 Jeanne Ettelson, president of ... popular and only free OCD support group in Chicago. ... for OCD sufferers, the group is lead by psychologists ... This allows group participants to learn accurate information ... Prevention. , “Participants in Beyond OCD’s support group ...
(Date:5/23/2013)... 23 (HealthDay News) -- Schools should ensure that ... activity each day to support their health and ... report. Although previous studies show 60 ... health and development, it,s estimated that only about ... this recommendation, according to the report from the ...
Breaking Medicine News(10 mins):Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2
... Experts on the Battle Against H1N1 , WASHINGTON, Oct. 8 ... of the House and Senate, the Aspen Institute and TIME magazine ... on what the looming changes will mean for the American people. ... Banquet and Conference Center, at the Reserve Officers Association, One Constitution ...
... Oct. 8 Health by Design of San Antonio, TX, ... individuals, has recently appointed Omar Rodriguez as Executive Vice President, ... in the health care arena, Rodriguez assumes a newly created ... its unique approach to medical care. His first area of ...
... , SILVER SPRING, Md., Oct. 8 The ... Food and Drug Administration, has filed a complaint for ... Calif., seeking to stop the company from manufacturing, producing, ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , The complaint ...
... have just learned they,re in the running for the 2009 Hutch ... one of whom will go on to receive the prestigious Hutch ... finalists for the 45th annual Hutch Award are: , Jonny ... Los Angeles Angels of Anaheim Mark Lowe, Seattle Mariners ...
... , The Prem Rawat Foundation,s grant to St. John of Jerusalem ... LOS ANGELES, Oct. 8 A $25,000 grant by The Prem ... (SJJEH) to provide eye care for 30,000 children in an area ... the West. Over 50% of the people in the Palestinian Territories, ...
... Australia and U.S., most patients recovering, death rate same ... -- Potentially foreshadowing the U.S. experience this fall and ... just gone through their flu season report "substantial" traffic ... H1N1 swine flu infections. , Because winter in the ...
Cached Medicine News:Health News:Tom Daschle, Richard Gephardt and Other Health Care Leaders to Diagnose Health Care Reform Battle in the Final Days of the Debate 2Health News:Tom Daschle, Richard Gephardt and Other Health Care Leaders to Diagnose Health Care Reform Battle in the Final Days of the Debate 3Health News:Health Care Industry Leader Joins Health by Design Executive Team 2Health News:FDA Takes Enforcement Action Against Ready-to-Eat Sandwich Manufacturer 2Health News:Ten Finalists Chosen for Hutch Award(R) 2Health News:TPRF Gives US$25,000 to Help Provide Eye Care for Children in Palestinian Territories 2Health News:Swine Flu May Bring Surge in Hospitalizations 2Health News:Swine Flu May Bring Surge in Hospitalizations 3